Leaders of the Senate Finance Committee on Friday unveiled an updated version of their bipartisan drug pricing bill, though it’s unclear if the changes will appease skeptical Republican senators.
The renewed push for Republican support by Chairman Charles E. Grassley of Iowa and the committee’s ranking Democrat, Ron Wyden of Oregon, comes ahead of a planned House vote next week on Democrats’ signature drug price negotiation bill.
A Senate panel approved President Donald Trump’s nominee to lead the Food and Drug Administration amid questions from both parties about the agency’s plans for regulating flavored e-cigarettes.
The Health, Education, Labor and Pensions Committee voted 18-5 to advance to the Senate floor the nomination of medical executive and doctor Stephen Hahn.
When President Donald Trump’s nominee to lead the Food and Drug Administration appears for the first time before a Senate panel on Wednesday, he’ll likely face tough questions about some policy issues that he may not have thought much about previously.
While the nominee, Stephen Hahn, is a highly regarded cancer doctor who has helped lead a research hospital with a budget nearly the size of the FDA’s, the confirmation hearing will be a reminder of the breadth of the agency’s work.
A new National Institutes of Health-funded study published Tuesday said that menthol flavoring is one of the least popular e-cigarette flavors among teenagers, amid speculation that the Trump administration may not include menthol in the flavored e-cigarette ban it proposed in September.
That proposal cleared the White House Office of Management and Budget on Monday afternoon, which is the last step before public release.
President Donald Trump on Friday announced he intends to nominate Stephen Hahn, a doctor and executive at one of the country’s leading cancer treatment hospitals, to be the next Food and Drug Administration commissioner.
Hahn is currently the chief medical executive at the MD Anderson Cancer Center in Houston. He is trained as a radiation oncologist, a field that uses radiation to kill cancer cells and tumors or slow their growth.
A House committee on Thursday approved a Democratic bill designed to limit drug prices, a top priority for the party, as another panel’s debate on the measure was poised to last for hours.
House leaders produced the 141-page bill after months of deliberations among various party factions, as progressives urged their colleagues to be bold despite GOP criticisms that the measure could hamper research into future cures. The bill, numbered HR 3, includes requirements for the Department of Health and Human Services to negotiate Medicare prices for the most expensive drugs, with commercial health plans also having the option of adopting those prices.
President Donald Trump’s top domestic policy adviser on Monday predicted that the White House could strike a deal with House Democrats on drug prices — if the impeachment inquiry into the president ultimately doesn’t go anywhere.
Domestic Policy Council Director Joe Grogan said House Democrats deserve credit for proposing a drug price bill, which he called ambitious. He said he met last week with Speaker Nancy Pelosi’s health care adviser, Wendell Primus, as well as House committee staff, and the two sides had a “great” conversation about the legislation.
The National Institutes of Health should do more to ensure that investigators and grant reviewers aren’t susceptible to foreign influence, according to a trio of reports from the Health and Human Services inspector general released Friday.
The inspector general recommended that the NIH enhance its vetting processes for the independent researchers who review grant applications. The agency could also do more to ensure that research institutions comply with requirements to ensure that investigators disclose all of their funding sources.
House Democrats on Thursday released the outline of a long-awaited drug price proposal, taking a step toward fulfilling one of the party’s signature campaign promises: requiring Medicare to negotiate drug prices.
The bill would allow commercial insurers to benefit from the Medicare-negotiated price as well, and base Medicare’s highest-acceptable price on the lower prices other wealthy countries pay.
Senators from both parties emphasized to the Food and Drug Administration on Thursday that more should be done to curb youth vaping beyond the Trump administration’s decision a day earlier to ban e-cigarette flavors.
Acting FDA Commissioner Ned Sharpless briefed the senators in a morning meeting that the organizer, Minority Whip Richard J. Durbin, D-Illinois, described in positive terms. Last week, Durbin called on Sharpless to resign if the FDA did not restrict flavored e-cigarette sales, but Durbin said Thursday that Sharpless “responded to my letter in a positive way and I want to give him a chance to show that he’s serious.”
The Trump administration on Wednesday said it planned to halt the sales of flavored e-cigarettes amid a national outbreak of lung illnesses that may be linked to vaping devices.
Health and Human Services Secretary Alex Azar said the Food and Drug Administration will issue a new policy within several weeks that will require all flavored e-cigarettes to come off the market.
A comprehensive drug price bill being developed by House Democrats would give private insurers the benefit of government-negotiated prices, according to a summary of the measure obtained by CQ Roll Call.
Under the Democrats’ draft plan, the government would set prices based on what is paid in other wealthy countries, according to the summary. That is similar to how a proposal by the Trump administration would work.
Lawmakers under pressure to address mass shootings could provide millions for research on gun violence, which would help fill a knowledge gap about policies that are most effective at reducing injuries and death, as Congress attempts to fund the government by Oct. 1.
House Democrats have proposed $50 million to study gun violence, and academics say the government funding could ensure that the data collection infrastructure is adequate to support a broad research enterprise.
The National Institutes of Health needs a “substantial infusion of funding” to address the “deteriorating condition” of many of its facilities, according to a congressionally mandated report.
The report, released Monday by the National Academies of Sciences, Engineering and Medicine, recommends that Congress provide $1.3 billion in new funding over several years in order to address buildings and facilities at the NIH’s campus in Bethesda, Maryland.
The Food and Drug Administration on Thursday proposed long-delayed graphic health warnings for cigarette packages, taking a step toward fulfilling a requirement of a decade-old smoking prevention law.
The new warning label proposal will now be subject to a public comment period, and is under a court-ordered deadline to be finalized by March 15, 2020.
Democrats in Congress are amplifying their calls to fund more research on gun violence after the recent mass shootings in Ohio and Texas, but Senate Labor-HHS-Education Appropriations Chairman Roy Blunt suggested Thursday he wouldn’t support new funding in that area.
The dispute over $50 million for gun violence prevention research could pose an additional challenge in the effort to avoid a government shutdown this fall.
Congress this year could enact the biggest overhaul of Medicare’s prescription drug benefit since it was first established in 2003. If successful, seniors — and taxpayers — would be more insulated against the cost of the most expensive drugs.
One proposed change is meant to help Medicare control the costs it absorbs so that the program’s premiums can remain stable despite increasing drug prices. Supporters of the drug program tout its low premiums, with the Trump administration and the private insurers who run Part D recently highlighting that average consumer premiums will fall in 2020.
The Trump administration on Wednesday announced plans to help states and others import lower-cost drugs from Canada, a popular but controversial idea that President Trump has embraced but that the Canadian government has pushed back on.
The plans outlined Wednesday will offer guidelines for setting up drug importation programs, but they also highlighted the challenges of this approach to lowering drug prices for consumers in the United States.
The Senate Finance Committee on Thursday approved, 19-9, a draft bill meant to reduce the cost of drugs in Medicare and Medicaid.
Only six of the panel’s 15 Republicans voted to advance the measure, joining all 13 Democrats. The most controversial amendments to the measure were rejected on mostly party-line votes.
The popular e-cigarette Juul is under renewed scrutiny by Congress thanks to two days of hearings that could pressure lawmakers to act on e-cigarette flavors that appeal to young people.
On Wednesday, the House Oversight and Reform Economic and Consumer Policy Subcommittee heard from witnesses about the company’s efforts to attract some vulnerable populations, namely teenagers and American Indians.
Save for later